



1617

\$

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/045,596

Filing Date

October 18, 2001

First Named Inventor

Paul A. Price

Group Art Unit

Theodore J. Criares

Examiner Name

1617

Total Number of Pages in This Submission

5

Attorney Docket Number

407T-893910US

## ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☒ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☒ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):
  - receipt acknowledgment postcard

### Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.C.

Signature

Date

July 9, 2003

RECEIVED  
JUL 17 2003  
TECH CENTER 1600/2900

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Amelia Groth

Signature

Date

July 9, 2003



#15  
7/20/03  
*[Signature]*

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents  
PO Box 1450, Alexandria, VA 22313-1450, on July 9, 2003  
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By: *[Signature]*  
Amelia Groth

Atty Docket No: 407T-893910US  
Client Ref: 2002-115-1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

**PAUL A. PRICE**

Examiner: Theodore J. Criares

Application No.: **10/045,596**

Art Unit: 1617

Filed: **10/18/2001**

For: **A FETUIN-MGP-MINERAL  
COMPLEX IN SERUM**

**RESPONSE TO RESTRICTION  
REQUIREMENT**

Assistant Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450  
Sir:

This paper is filed in response to the Office Action dated March 25, 2003 containing a Restriction Requirement. The following documents are enclosed herewith:

- 1) A petition to extend the period of response for three months.

**REMARKS**

In the March 25, 2003 Office Action the Examiner required restriction to one of the following groups under 35 U.S.C. §121:

Group I: Claims 1-12, drawn to a method of determining the risk for calcification of arteries and other tissues in mammals;

Group II: Claims 13-21, drawn to a method of screening for an agent that reduces or ameliorates one or more symptoms of the calcification of arteries and other soft tissues;

Group III: Claims 22-31, drawn to a method of monitoring the efficacy of a treatment for one or more symptoms of calcification of arteries and other soft tissues in a mammal;

Group IV: Claims 33-43, drawn to a method of determining the risk for atherosclerosis in a mammal;